Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

05-22   

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


Declaração: Este artigo é reproduzido em outras mídias. O objetivo da reimpressão é transmitir mais informações. Isso não significa que este site concorda com suas opiniões e é responsável por sua autenticidade, e não tem nenhuma responsabilidade legal. Todos os recursos deste site são coletados na Internet. O objetivo do compartilhamento é apenas para o aprendizado e a referência de todos. Se houver violação de direitos autorais ou propriedade intelectual, deixe uma mensagem.

Mais recentes

  • Inauguração da Exposição Digital do Comércio Internacional China-América Latina de 2022

    No dia 20 de Setembro de 2022 foi inaugurada a Exposição Digital de Comércio Internacional China-América Latina na plataforma B2B www.matchupexpo.com. A exposição é organizada pelo China Council for the Promotion of International Trade e co-realizada pela China Chamber of International Commerce e pela Jiangsu United Asia International Exhibition Co., Ltd. Esta exposição digital contará com um modelo inovador de 10 dias de exposição online + 30 dias de comércio online + 365 dias de exposição online. Tem por objectivo aprofundar a cooperação em campos tradicionais, expandir a cooperação em indús
  • GEM, a Leading Green Enterprise in China, will land on the Swiss Exchange

    GEM (stock code: 002340), a company listed on the Shenzhen Stock Exchange, announced that on June 22, 2022, that the China Securities Regulatory Commission (CSRC) gave its approval for the company to issue global depository receipts (GDR) and to be listed on the Swiss Exchange (SIX). On July 20, 2022, SIX approved GEM to issue GDR and to be listed on the SIX. So far, the path of GEM issuing GDR and going public on the SIX have been unimpeded.
  • Lançado oficialmente! “O 1º Pod Mod Descartável” ZOVOO DRAGBAR R6000 revela o mistério

    O lançamento do novo produto ZOVOO 2022 foi transmitido em directo para todo o mundo no dia 29 de Junho. A ZOVOO lançou 4 novos produtos revolucionários, a tecnologia de núcleo cerâmico GENE TREE Special Edition, e o desempenho de topo no campo da atomização electrónica. O excelente desempenho da ZOVOO conquistou todos de novo, atraindo a atenção de numerosos meios de comunicação, parceiros e fãs globais.
  • Desempenho de Topo!O Lançamento Global Online ZOVOO 2022 será realizado em breve

    O Lançamento Global Online de Produtos ZOVOO 2022 terá início às 22 horas (GMT+8) do dia 29 de Junho. A ZOVOO vai atingir um novo pico no campo do vaping com a nova experiência que os produtos de vaping descartáveis ultrapassam de forma abrangente, e definir um novo padrão de vapes descartáveis na nova era.
  • Alcançando novos patamares, a VOOPOO ganhou 3 prémios na SÉTIMA CERIMÓNIA ANNUAL DOS PRÉMIOS VAPOUROUND

    No dia 27 de Maio, hora de Birmingham, realizou-se no The National Conference Centre em Birmingham, Reino Unido, a 7ª cerimónia de entrega de prémios realizada pela Vapouround, uma organização de meios de comunicação social com autoridade em matéria de atomização electrónica. A VOOPOO, a marca líder na indústria da atomização electrónica, foi mais uma vez amplamente reconhecida pelos organizadores e por muitos utilizadores, e os seus produtos ganharam três prémios, Melhor Sistema de Pod, Melhor Mod, e Melhor Fabrico.
  • Exposição On-line (Oriente Médio e Europa) realizada com sucesso pela Zhejiang Indústria e Comércio de Móveis Famosos

    Patrocinado pela Zhejiang CCPIT e organizado pela Yiwu Boyu Exhibition Service Co., a exposição 2022 on-line (Oriente Médio e Europa) da Zhejiang Indústria e Comércio de Móveis Famosos, foi realizada com sucesso com fechamento em 21 de maio, totalizando 1.8 milhão de dólares americanos em negócios realizados.
  • “Meta One” Will Launch Mobile App Soon!

    Metaverse Federation and Metaverse Federation University and the Meta Time together announced that “Meta One” will officially launch for mobile App on May 20th, 2022!
  • Aviso de exposição | A famosa exposição na industria de móveis de Zhejiang ( Europa central e oriental ) feira on-line com início dia 17 até 21 de maio.

    Como suporte às empresas de móveis de Zhejiang e com o intuito de explorar o mercado internacional, o Conselho para a promoção do Comercio Internacional de Zhejiang irá apresentar à famosa exposição da indústria de móveis de Zhejiang(Europa central e oriental) 2022 de 17 até 21 de maio para ajudar as empresas expandir à participação no mercado da Europa central e oriental, através do marketing digital.
  • A história da VOOPOO e Spark Your Life

    Em 11 de abril de 2022, a VOOPOO lançou seu produto anual, o ARGUS GT 2. Com sua saída constante de alta potência de 200W, classificação IP68 e design de cratera vulcânica, o ARGUS GT 2 traz uma experiência mais inovadora para os usuários de todo o mundo.

Link

Back to top
© Copyright 2006-2020 ptnews.club      Contate-nos   SiteMap